1. Introduction {#j_med-2019-0013_s_001}
===============

Electronic pathology reports, an important component of electronic health records \[[@j_med-2019-0013_ref_001]\], often document valuable data for research and quality control \[[@j_med-2019-0013_ref_002]\]. For breast cancer, the data documented in pathology reports is especially important since the expression statuses of hormone receptors, such as the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (ErbB2 or Her-2), are immunohistochemically examined \[[@j_med-2019-0013_ref_003], [@j_med-2019-0013_ref_004], [@j_med-2019-0013_ref_005]\] and documented in pathology reports. Expression of these markers not only affects prognosis \[[@j_med-2019-0013_ref_006], [@j_med-2019-0013_ref_007]\] but also has implications on the choice of hormone therapy and chemotherapy \[[@j_med-2019-0013_ref_008], [@j_med-2019-0013_ref_009]\]. The importance of these markers in the treatment of breast cancer has been widely recognized and incorporated in the most recent (eighth) version of the American Joint Committee on Cancer staging system \[[@j_med-2019-0013_ref_010]\].

The statistics on ER, PR, and Her-2 immunostaining results are important quality indicators for pathology laboratories. Comparison of these statistics with the literature, may highlight possible problems in the quality of immunohistochemistry. For this reason, the accreditation process of the College of American Pathologists requires yearly ER, PR, and Her-2 immunostaining results \[[@j_med-2019-0013_ref_011]\]. Moreover, due to the possible value of the hormone receptor expression status on the prediction of local recurrence \[[@j_med-2019-0013_ref_012]\], statistics of hormone receptor expression status is also valuable for research on recurrent breast cancer.

To obtain hormone receptor expression statistics, some hospitals utilize a synaptic pathology report system \[[@j_med-2019-0013_ref_013], [@j_med-2019-0013_ref_014], [@j_med-2019-0013_ref_015]\] in which pathologists enter structured data. Since this approach requires a behavioral change by pathologists, it is not widely applied, and pathology reports remain stored in pure text form. To retrieve these free-text data, a text mining approach must be used to avoid manual work. However, most general medical text mining utilities do not specifically process tokens about immunohistochemical (IHC) findings \[[@j_med-2019-0013_ref_016]. [@j_med-2019-0013_ref_017]\], and the few tools that handle IHC data use sophisticated natural language processing (NLP) methods, such as subgraph mining and factorization \[[@j_med-2019-0013_ref_018], [@j_med-2019-0013_ref_019]\], which require computing powers that are not affordable in the general hospital information system. Moreover, even within these sophisticated tools, no function can yet discriminate between primary and recurrent disease, which makes a comparison of hormone receptor expression between primary and recurrent disease impossible with these tools.

Since focused mining of IHC study data is of small scope, simple methods, such as word/phrase matching, concept-match scrubbing \[[@j_med-2019-0013_ref_020]\], and semantic, grammar-based, concept finding \[[@j_med-2019-0013_ref_021]\], if combined with clinical knowledge, may still achieve good results at a small scale. The current study describes a method to mine IHC data from pathology reports documenting either primary or recurrent breast cancer, using regular expression-based word/phrase matching.

2. Materials and methods {#j_med-2019-0013_s_002}
========================

2.1. Data retrieval and pre-processing {#j_med-2019-0013_s_002_s_001}
--------------------------------------

All pathology reports issued by the China Medical University Hospital (CMUH) from 2013 to 2017 were exported in pure text form, by a client mentored by Mr. Chi-Sung Wei from the Department of Information. The patient data within the text file was then automatically de-identified by the method described by Neamatullah *et al*. \[[@j_med-2019-0013_ref_022]\] to eliminate violation of privacy and ethical concern. To accelerate the information retrieval from reports, the text files were then archived into a client-side SQLite3 database. [Figure 1](#j_med-2019-0013_fig_001){ref-type="fig"} illustrates the data retrieval and pre-processing steps. Due to the nature of the study, no ethical approval was required.

![Data retrieval and pre-processing steps.](med-14-091-g001){#j_med-2019-0013_fig_001}

2.2. Searching for primary and local recurrent breast cancer cases {#j_med-2019-0013_s_002_s_002}
------------------------------------------------------------------

Most pathology reports in our institute, as in many other hospitals, are written according to the format suggested by "Rosai and Ackerman's Surgical Pathology" \[[@j_med-2019-0013_ref_023]\], and the diagnoses are written in the following format: "Organ name, side/position, surgical procedure, diagnosis". Tokens in the diagnosis section of the pathology report can then be searched according to this format. In the method designed in the current study, the program will first search for organ names "breast" or "chest wall", the sites in which primary or recurrent breast cancer occur. ". If the organ name matches the previous criteria, the program will then search for tokens related to invasive carcinoma.

For pathology reports starting with the organ name "breast", the program will first match for the keyword "carcinoma". If the keyword "carcinoma" is present in a diagnosis, the program will then check if a diagnosis contains keywords that represent carcinoma *in situ* in the World Health Organization definition \[[@j_med-2019-0013_ref_024]\]. All cases that contain the token "carcinoma" and do not contain keywords that represent carcinoma *in situ* will then be included in the breast cancer case list. Cases that represent local, ipsilateral recurrent carcinoma are detected by presence of token "recurrent" or "recurrence". All cases represent new biopsy at the site of recurrent that confirmed the diagnosis once the recurrence occurred.

For pathology reports starting with the organ name "chest wall", all cases with the token "carcinoma" and "breast origin" will be included for analysis and marked as recurrent breast cancer, since all these cases represent local, ipsilateral recurrent carcinoma. [Figure 2](#j_med-2019-0013_fig_002){ref-type="fig"} shows the search protocol.

![Protocol to search for primary and recurrent breast cancer cases.](med-14-091-g002){#j_med-2019-0013_fig_002}

2.3. Two-stage data mining approaches for hormone receptor data {#j_med-2019-0013_s_002_s_003}
---------------------------------------------------------------

For mining of hormone receptor status examined by immunohistochemistry, a two-stage mining approach was designed in the current study, by first extracting the paragraph that may contain IHC study data and then attempting to retrieve ER, PR, and Her-2 results from the mined paragraph. This approach, which is depicted in [Figure 3](#j_med-2019-0013_fig_003){ref-type="fig"}, enhances the execution speed and minimizes the extraction error by matching only a small target, rather than the whole report for IHC study data.

![Protocol for mining of hormone receptor data.](med-14-091-g003){#j_med-2019-0013_fig_003}

### 2.3.1. Identification of paragraphs containing IHC study results {#j_med-2019-0013_s_002_s_003_s_001}

To optimize executing speed, a two-step regular expression matching engine for IHC study extraction was designed. In the first step, the program will attempt to match three common forms of IHC study result expression. The first form of reporting IHC study results consists of a separate paragraph in the pathology report, written in multiple rows separated by a line break ([Figure 4](#j_med-2019-0013_fig_004){ref-type="fig"}). In this procedure, every different marker is placed on a new row. The second form comprises a separate paragraph in the pathology report written without a line break. In this approach, the different markers are separated by commas ([Figure 5](#j_med-2019-0013_fig_005){ref-type="fig"}). The third protocol consists of a sentence in the microscopic description, as shown in [Figure 6](#j_med-2019-0013_fig_006){ref-type="fig"}. The identification of paragraphs therefore involves matching the text with one of following regular expression patterns: \["\[Ii\]mmunohisto.\*\\)", "\[Aa\]ncillary.\*\\)", and "\[Ii\]mmunostain.\\)".

![Reporting immunohistochemical study result as a solitary paragraph with multiple rows.](med-14-091-g004){#j_med-2019-0013_fig_004}

![Reporting immunohistochemical study result as a solitary paragraph, with different studies separated by commas.](med-14-091-g005){#j_med-2019-0013_fig_005}

![Reporting immunohistochemical study result as a sentence in the microscopic description.](med-14-091-g006){#j_med-2019-0013_fig_006}

Paragraphs extracted from this step will then undergo extraction of the IHC study result ([section 2.3.2](#j_med-2019-0013_s_002_s_003_s_002){ref-type="sec"}).

### 2.3.2. Extraction of IHC study results {#j_med-2019-0013_s_002_s_003_s_002}

To extract the results of each separate marker can be a difficult task since there can be unlimited ways to write these results. For institutes that are routinely accredited by the College of American Pathologists (CAP), such as our institute, the format of reporting ER, PR, and Her-2 results is regulated by guidelines \[[@j_med-2019-0013_ref_025], [@j_med-2019-0013_ref_026]\]. Therefore, in the method described herein, the ER, PR, and Her-2 results are matched and extracted according to the guidelines.

For ER and PR, it is required that pathologists first report the positivity findings. If the result is positive, the expression percentage should be documented. For pathologists who comply to the guideline, it would result in three patterns: "ER/PR (positive, \_\_%)", "ER/PR: positive, \_\_%", and "ER (positive)". The paragraphs containing ER/PR results are parsed by matching the following regular expression: "er\\ \*\[\\:\\(\]" and "pr\\ \*\[\\:\\(\]", while the percentages are by matching the following regular expression: "\[0-9\]+\\%"

For Her-2 results, pathologists must report both the positivity (positive, equivocal, negative) and score (0, 1+, 2+, and 3+). Compliance with this guideline, would result in two patterns: "Her-2/Her2/HER2/HER-2 (positive/equivocal/negative, 0/1+/2+/3+ or score 0/1/2/3)" and "Her-2/Her2/HER2/HER-2 (positive/equivocal/negative, 0/1+/2+/3+ or score 0/1/2/3, weak/moderate/strong staining in \_\_%)". The paragraphs containing Her-2 result are parsed by the matching the following regular expression

pattern: "her-\*2\\ \*\[\\:\\(\]", while the Her-2 scores are parsed by matching the following regular expression pattern: "score\\ \[0-9\]+", "\[0-9\]\\+".

2.4. Recording of results {#j_med-2019-0013_s_002_s_006}
-------------------------

The results are exported into a comma-separated text (CSV) file by the program, recording each case in the form: "case ID, cell type, ER result, PR result, Her-2 result, Recurrent or Primary disease". If there is a failed extraction, the result is recorded as "None".

2.5. Validation of results {#j_med-2019-0013_s_002_s_007}
--------------------------

All cases and IHC study results were reviewed by two board-certificated pathologists (Kai-Po Chang and John Wang), for validation.

2.6. Statistical analysis {#j_med-2019-0013_s_002_s_008}
-------------------------

For comparison of the hormone receptor results between primary and recurrent breast cancer, Pearson's chi-squared test with Yates' continuity correction was done using the MASS package of R 3.5.1 for Windows 10

3. Results {#j_med-2019-0013_s_003}
==========

3.1. Total case number {#j_med-2019-0013_s_003_s_001}
----------------------

Our program identified a total of 3806 invasive breast carcinoma cases, of which 3762 were primary breast cancer, and 44 were local recurrent breast cancer. The cases were all correctly identified and verified.

3.2. Effectiveness of IHC study result detection and extraction {#j_med-2019-0013_s_003_s_002}
---------------------------------------------------------------

The ER IHC study was done in 3768 of 3806 breast cancer cases. The expression status result was correctly extracted in 3723 cases, yielding a sensitivity of 98.8%. The PR IHC study was done in 3733 of 3806 breast cancer cases. The expression status result was correctly extracted in 3685 cases (98.7% sensitivity). The Her-2 IHC study was done in 3738 of 3806 breast cancer cases. The expression status result was correctly extracted in 3679 cases (98.4% sensitivity). The result is shown in [Table 1](#j_med-2019-0013_tab_001){ref-type="table"}.

###### 

Summary of results of the extraction of immunohistochemical study result data.

  Marker   Total sample number   Number of results correctly detected   Sensitivity
  -------- --------------------- -------------------------------------- -------------
  ER       3768                  3723                                   98.8%
  PR       3733                  3685                                   98.7%
  Her-2    3738                  3679                                   98.4%

3.3. Comparison of hormone receptor expression between primary and recurrent breast cancer {#j_med-2019-0013_s_003_s_003}
------------------------------------------------------------------------------------------

Of 3723 cases with ER IHC study results, 3679 had primary disease, and 44 had local recurrent disease. Among 3679 primary disease cases, 2814 were ER-positive (76.5%). Among 44 recurrent disease cases, 24 were ER-positive (54.5%). It indicates that primary disease is is more prone to be ER-positive than recurrent disease (χ^2^=10.374, df=1, p=0.001278). The result is shown in [Table 2](#j_med-2019-0013_tab_002){ref-type="table"}.

###### 

Difference in ER expression between primary and recurrent breast cancer.

  ER result                       Primary breast cancer   Recurrent breast cancer
  ------------------------------- ----------------------- -------------------------
  Positive                        2814                    24
  Negative                        865                     20
  Positive rate                   76.5%                   54.5%
  χ^2^=10.374, df=1, p=0.001278                           

Of 3685 cases with machine-identified PR IHC study results, 3642 were primary disease, and 43 were local recurrent disease. Among 3642 primary disease cases, 2299 were PR-positive (63.1%). Among 43 recurrent disease cases, 18 were PR-positive (41.9%). It indicates that primary disease is more prone to be PR-positive than recurrent disease (χ^2^=7.3467, df=1, p=0.006719). The result is shown in [Table 3](#j_med-2019-0013_tab_003){ref-type="table"}.

###### 

Difference in PR expression between primary and recurrent breast cancer.

  PR result                       Primary breast cancer   Recurrent breast cancer
  ------------------------------- ----------------------- -------------------------
  Positive                        2699                    18
  Negative                        1343                    25
  Positive rate                   63.1%                   41.9%
  χ^2^=7.3467, df=1, p=0.006719                           

Of 3679 cases with machine-identified Her-2 IHC study results, 3636 had primary disease, and 43 had recurrent disease. Among 3642 primary disease cases, 589 were Her-2-positive (defined as score 3+) by IHC criteria, 1024 were Her-2-equivocal (defined as score 2+), and 2023 were Her-2-negative (defined as score 0 or 1+; 1074 with score 0 and 949 with score 1+). The overall Her-2 positivity is therefore 16.2% in primary breast cancer. Among 43 recurrent disease cases, 21 were Her-2-positive (48.8%), 12 were Her-2-equivocal (27.9%), and 10 were Her-2-negative (23.2%; 6 with score 0 and 4 with score 1+). It indicates the recurrent disease is more prone to be Her-2 positive than recurrent disease (χ^2^=35.449, df=3, p=9.79e-8). The result is shown in [Table 4](#j_med-2019-0013_tab_004){ref-type="table"}.

###### 

Difference in Her-2 expression between primary and recurrent breast cancer.

  Her-2 result                                   Primary breast cancer          Recurrent breast cancer
  ---------------------------------------------- ------------------------------ -------------------------
  Score 0                                        1074                           6
  Score 1                                        949                            4
  Score 2                                        1024                           12
  Score 3                                        589                            21
  Positive rate (positive defined as score 3+)   16.2%                          48.8%
                                                 χ^2^=35.449, df=3, p=9.79e-8   

This observation that the recurrent disease is more prone to be ER-negative, PR-negative, and Her-2-positive is consistent with the previous literature \[[@j_med-2019-0013_ref_012]\].

4. Discussion {#j_med-2019-0013_s_004}
=============

4.1. Sensitivity issue of regular expression-based word/phrase matching {#j_med-2019-0013_s_004_s_001}
-----------------------------------------------------------------------

The proposed program failed to detect and extract hormone receptor data in some cases (1.2% for ER, 1.3% for PR, and 1.6% for Her-2). Most of these were caused by failure to detect phrases containing the IHC study result. During the manual examination of the failed cases, at least three alternative ways other than our target are found. These alternative patterns included "The immunohistochemical study......", "Ancillary study for tumor cells......", "Tumor immunoprofile:", and *vice versa*. There are simply too many ways to express the IHC study result, so the simple regular expression-based word/phrase matching strategy

cannot be expected to match all pathologic reports that contain these data.

In some cases, the IHC study paragraph was identified, but the program still failed to extract one or more of the hormone receptor data. In this situation, the issue was in the expression pattern of the hormone receptors. For example, the program aimed at the phrase "ER (positive, 90%)" or "ER: positive, strong expression in 90%", for extraction of ER positivity and percentage, but this is not the only pattern that can be used to write the ER expression. For example, some pathologists prefer a narrative form, and report the ER expression status as "The tumor is positive for ER". For positivity, some pathologists prefer the shorter phrase "ER+" rather than "ER positive". These variant writing habits of pathologists accounted for some cases in which the program failed to detect ER or PR data.

Writing habit is an even more serious issue in Her-2 data extraction because this tumor marker can be expressed in numerous ways, including "Her-2/*neu*", "HER2", or "Her-2". Moreover, not all pathologists report the Her-2 result according to the CAP recommendation. For instance, if a Her-2 IHC slide is positive according to the regulation, it should be reported as "Her-2: positive, score 3+" or "Her-2: positive, score 3/3". However, some pathologists merely report it as positive, without mentioning the score, or write the score as "+++" rather than "3+". For human interpreters, these expressions are readable without any difficulty but, for the machine, it represents a problem.

In general, though the proposed program achieved acceptable sensitivity, regular expression-based text mining does have its limitations.

4.2. Possible direction for further development of NLP engine for hormone receptor status mining {#j_med-2019-0013_s_004_s_002}
------------------------------------------------------------------------------------------------

This study demonstrated the limitations of the conventional expression-based approach. To solve the issue of variable syntax used in pathology reports, distributional semantic modeling \[[@j_med-2019-0013_ref_027]\] may be a solution. For distributional semantic modeling, a large enough text corpus is first built from pathology reports. The semantic modeling engine then analyzes relationships between words in the corpus. In this way, similar phrases that are close to the mining target can be learned and included in the mining algorithm. Distributional semantics have been used successfully in searching the medical literature when an appropriate corpus is given \[[@j_med-2019-0013_ref_028]\], and it would have a role in the mining of hormone receptor data as well.

Another promising method for hormone receptor status mining is neurolinguistics. Since the syntax variations in electronic health records are due to differences in expression of natural language, some researchers have achieved a good result in data mining of medical texts, by applying models that imitate the human brain \[[@j_med-2019-0013_ref_029], [@j_med-2019-0013_ref_030]\]. Given the difficulty in mining hormone receptor status also comes from syntax variability, neurolinguistics modeling may further increase the sensitivity of data detection described in the current study.

In conclusion, the proposed method achieved a good result in mining the hormone receptor status from breast cancer cases, but it can still be improved. With the progression of NLP technology and computing power, the obstacle encountered in this study may eventually be resolved.

4.3. Limitation of hormone receptor status comparison between primary and recurrent breast cancer via data mining {#j_med-2019-0013_s_004_s_003}
-----------------------------------------------------------------------------------------------------------------

The present article demonstrated a significant difference in the hormone receptor expression between primary and recurrent breast cancer, which is consistent with previous literature \[[@j_med-2019-0013_ref_012]\]. However, the statistical power of this result is limited, due to the relatively small sample number of recurrent breast cancer cases. Two inherent limitations of acquiring cases of recurrent disease via data mining of pathology reports exist. The first one is the scarcity of recurrent breast cancer cases in pathology archives because some of the recurrent cancer cases are diagnosed by imaging, and no tissue is sent to the pathology department for validation. The other limitation is the under-reporting of recurrent diseases. Even if a case of recurrent breast cancer is sent to the pathology department for tissue confirmation, it may not be correctly reported as recurrent disease.

To solve these issues, the case number can be expanded by combining data from multiple institutes, to increase the total number of recurrent diseases or deeper mining of the health record database can be performed, to directly detect recurrent disease from the patient history, thereby avoiding the problem of under-reporting. With future expansion of the database and improved data mining algorithms, data mining can have a great impact on recurrent breast cancer research.
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Click here for additional data file.
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